156 related items for PubMed ID: 8065017
1. [Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin].
Okamoto M, Maruyama F, Tsuzuki M, Nomura T, Miyazaki H, Wakita M, Kojima H, Sobue R, Matsui T, Ino T.
Rinsho Ketsueki; 1994 Jul; 35(7):635-41. PubMed ID: 8065017
[Abstract] [Full Text] [Related]
2. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[Abstract] [Full Text] [Related]
3. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY.
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[Abstract] [Full Text] [Related]
4. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M, Leonard J, Shuster MW, Kaufman TP.
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[Abstract] [Full Text] [Related]
5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[Abstract] [Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB.
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[Abstract] [Full Text] [Related]
7. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M.
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[Abstract] [Full Text] [Related]
8. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[Abstract] [Full Text] [Related]
9. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A, Martino R, Perea G, Ribera JM, López-Guillermo A, Guardia R, Escoda L, Altés A, Sierra J, Montserrat E.
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[Abstract] [Full Text] [Related]
10. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[Abstract] [Full Text] [Related]
11. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F.
Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
[Abstract] [Full Text] [Related]
12. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[Abstract] [Full Text] [Related]
13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[Abstract] [Full Text] [Related]
14.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
15. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
Li YH, Jiang WQ, Huang HQ, Zhang L, Liu DG, Xu RH, Zhou ZM, Sun XF, Lin TY, Xu GC, He YJ, Guang ZZ.
Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
[Abstract] [Full Text] [Related]
16. [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Bo LJ, Liang AB, Liu B, Chen YH, Wang F, Jin XP.
Ai Zheng; 2006 Dec; 25(12):1553-6. PubMed ID: 17166385
[Abstract] [Full Text] [Related]
17. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M.
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[Abstract] [Full Text] [Related]
18. Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.
Vitolo U, Orsucci L, Bertini M, Cavallero G, Gallamini A, Ghio R, Levis A, Rota-Scalabrini D, Resegotti L.
Haematologica; 1991 Oct; 76(1):43-6. PubMed ID: 2055560
[Abstract] [Full Text] [Related]
19. Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Herbrecht R, Damonte JC, Dufour P, Maloisel F, Liu KL, Ortiz S, Bergerat JP, Oberling F.
Semin Oncol; 1992 Feb; 19(1 Suppl 1):7-10. PubMed ID: 1384135
[Abstract] [Full Text] [Related]
20. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease.
Ribrag V, Nasr F, Bouhris JH, Bosq J, Brault P, Girinsky T, Cosset JM, Munck JN, Corti C, Decaudin D, Pico JL, Hayat M, Carde P.
Bone Marrow Transplant; 1998 May; 21(10):969-74. PubMed ID: 9632268
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
